Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis

Leukemia Research

Volumn 36, Issue 11, 2012, Pages 1380-1386

  Leitch, Heather A ^a   Chan, Christopher ^b   Leger, Chantal S ^a   Foltz, Lynda M ^a   Ramadan, Khaled M ^a   Vickars, Linda M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Iron chelation therapy; Lower IPSS risk; MDS; Myelodysplastic syndrome; RARS; Survival

Indexed keywords

DEFERASIROX; DEFEROXAMINE; ERYTHROPOIETIN; FERRITIN; LENALIDOMIDE;

AGED; APLASTIC ANEMIA; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMANS; IRON CHELATING AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84866331866     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.08.001     Document Type: Article

References (42)

1. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91(December (12)):1588-1590.
2. Malcovati L., Della Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23(October (30)):7594-7603.
3. Sanz G., Nomdedeu B., Such E., Bernal T., Belkaid M., Ardanaz T., et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008, 112(11):238-239.
4. De Swart L., Smith A., Fenaux P., Bowen D., Sanz G., Hellstrom-Lindberg E., et al. Transfusion-dependency is the most important prognostic factor for survival in 1000 newly diagnosed MDS pateints with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS Registry. Blood 2011, 118(21):1195-1196.
5. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(August (23)):3503-3510.
6. Neukirchen J., Fox F., Kündgen A., Nachtkamp K., Strupp C., Haas R., et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res 2012, 36(August (8)):1067-1070. [Epub 2012 May 6].
7. Leitch H.A., Leger C.S., Goodman T.A., Wong K.K., Wong D.H.C., Ramadan K.M., et al. Improved survival in red blood cell transfusion dependent patients with myelodysplastic syndrome receiving iron chelation therapy. Clinical Leukemia 2008, 2(3):205-2011.
8. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve suvival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010, 34(7):864-870.
9. Raptis A., Duh M.S., Wang S.T., Dial E., Fanourgiakis I., Fortner B., et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 2010, 50(January (1)):190-199.
10. Komrokji R.S., Sekeres M.A., List A.F. Management of lower-risk myelodysplastic syndromes: the art and evidence. Curr Hematol Malig Rep 2011, 6(June (2)):145-153.
11. Lyons R.M., Marek B.J., Sharma S., Paley C., Esposito J., Garbo L., et al. 24-Month analysis of the impact of chelation on clinical outcomes in a 600 patient registry of lower-risk MDS patients. Blood 2011, 118(21):1207a-1208a. [abstract 2800].
12. Chee C.E., Steensma D.P., Hanson C.A., Tefferi A. Neither serum ferritin nor number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Blood 2007, 110(November (11)):723a.
13. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51(June (2)):189-199.
14. Vardiman J.W. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem Biol Interact 2010, 184(March (1-2)):16-20. [Review].
15. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(March (6)):2079-2088.
16. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83(November (11)):858-861.
17. Jabbour E., Garcia-Manero G., Taher A., Kantarjian H.M. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist 2009, 14(May (5)):489-496.
18. Komrokji R.S., Al Ali N.H., Corrales-Yepez M., Padron E., Epling-Burnette P.K., Lancet J.E., et al. Impact of iron overload in higher risk myelodysplastic syndromes. Blood 2011, 118(21):1197. [abstract].
19. Kaloyannidis P., Yannaki E., Sakellari I., Bitzioni E., Athanasiadou A., Mallouri D., et al. The impact of desferrioxamine postallogeneic hematopoietic cell transplantation in relapse incidence and disease-free survival: a retrospective analysis. Transplantation 2010, 89(February (4)):472-479.
20. Steensma D.P. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep 2011, 6(June (2)):136-144. [Review].
21. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89(February (3)):739-761.
22. Porter J.B. Practical management of iron overload. Br J Haematol 2001, 115(November (2)):239-252.
23. Callens C., Coulon S., Naudin J., Radford-Weiss I., Boissel N., Raffoux E., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 2010, 207(April (4)):731-750.
24. Eberhard Y., McDermott S.P., Wang X., Gronda M., Venugopal A., Wood T.E., et al. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood 2009, 114(October (14)):3064-3073.
25. Gattermann N., Rachmilewitz E.A. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2011, 90(January (1)):1-10. [Review].
26. Ghoti H., Amer J., Winder A., Rachmilewitz E., Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007, 79(December (6)):463-467.
27. Jiang Y., Xue Z.H., Shen W.Z., Du K.M., Yan H., Yu Y., et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia 2005, 19(July (7)):1239-1247.
28. Ohyashiki J.H., Kobayashi C., Hamamura R., Okabe S., Tauchi T., Ohyashiki K. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1. Cancer Sci 2009, 100(May (5)):970-977.
29. Chan L.S.A., Buckstein R., Reis M.D., Chesney A., Lam A., Cheung M.C., et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML?. Blood 2008, 112(11):928a.
30. Gattermann N., Finelli C., Porta M.D., Fenaux P., Ganser A., Guerci-Bresler A., et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010, 34(September (9)):1143-1150.
31. List A.F., Baer M.R., Steensma D., Raza A., Esposito B., Virkus J., et al. Deferasirox (ICL670; Exjade) reduces serum ferritin (SF) and labile plasma iron (LPI) in patients with myelodysplastic syndromes (MDS). Blood 2008, 112(11):523a.
32. Chan L.S.A., Gu L.C., Rauh J.J., Wells R.A. Iron overload accelerates development of leukaemia: evidence from a mouse model. Blood 2010, 116(21):59a-60a. [abstract 122].
33. Della Porta M.G., Rosti V., Galli A., Travaglino E., Santambrogio P., Marseglia C., et al. The effects of mitochondrial ferritin expression in normal and sideroblastic erythropoiesis. Blood 2009, 114(22):306-307. [abstract].
34. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89(October (10)):1187-1193.
35. Davis B.A., O'Sullivan C., Jarritt P.H., Porter J.B. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004, 104(July (1)):263-269.
36. Gabutti V., Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996, 95(1):26-36.
37. Telfer P.T., Prestcott E., Holden S., Walker M., Hoffbrand A.V., Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000, 110(September (4)):971-977.
38. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 2009, 114(December (26)):5251-5255.
39. Leitch H.A. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. Drugs 2011, 71(January (2)):155-177. [Review].
40. Malcovati L., Pappaemmanuil E., Hellstrom-Lindberg E., Boultwood J., Bowen D., Vyas P., et al. Somatic mutatio of SF3B1, a gene encoding a core component of RNA splicing machinery, in myelodysplasia with ring sideroblasts. Blood 2011, 118(21):3-4.
41. Messa E., Carturan S., Maffe C., Pautasso M., Bracco E., Roetto A., et al. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 2010, 95(August (8)):1308-1316. [Research Support, Non-U.S. Gov't].
42. Steensma D.P., Bennett J.M. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006, 81(January (1)):104-130.